Showing results (991-1000 of 2,345) with videos related to

Sort By:
Pageof 235
The AAPS Journal|September 19, 2022
Sinusoidal Organic Anion-Transporting Polypeptide 1B1/1B3 and Bile Canalicular Multidrug Resistance-Associated Protein 2 Play an Essential Role in the Hepatobiliary Disposition of a Synthetic Cyclic Dinucleotide (STING Agonist)Philip Sandoval, Bei-Ching Chuang, John K Fallon, et al.
The AAPS Journal|September 20, 2022
Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple MyelomaHao Cai, Satoko Kakiuchi-Kiyota, Robert Hendricks, et al.
The AAPS Journal|August 29, 2022
Scientific Considerations for Stability Studies of Drug Substances Supporting Abbreviated New Drug Applications (ANDAs)Jizhou Wang, Neeru Takiar
The AAPS Journal|February 24, 2022
State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation ReferencesGiovanni Bocci, Tudor I Oprea, Leslie Z Benet
The AAPS Journal|April 28, 2019
A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD PatientsEva Germovsek, Claire Ambery, Shuying Yang, et al.
The AAPS Journal|May 1, 2019
Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission TomographyIrene Hernández Lozano, Rudolf Karch, Martin Bauer, et al.
The AAPS Journal|April 25, 2019
Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo EvidenceAna Cláudia Santos, Irina Pereira, Mariana Magalhães, et al.
The AAPS Journal|August 22, 2018
Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?Marden Emily, Ntai Ioanna, Bass Scott, et al.
The AAPS Journal|October 27, 2021
Understanding In Vivo Dissolution of Immediate Release (IR) Solid Oral Drug Products Containing Weak Acid BCS Class 2 (BCS Class 2a) DrugsMin Li, Xinwen Zhang, Di Wu, et al.
The AAPS Journal|February 12, 2022
Analytical Quality by Design, Life Cycle Management, and Method ControlThorsten Verch, Cristiana Campa, Cyrille C Chéry, et al.
Pageof 235